DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Conditions: Non-small Cell Lung Cancer Interventions: Drug: DZD9008 plus Bevacizumab Sponsors: Dizal Pharmaceuticals Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials